Top Page
Guangzhou Baiyunshan Pharmaceutical Holdings Company
(OTC:0874)
Guangzhou Baiyunshan Pharmaceutical Holdings Company (0874) vs. iShares MSCI Hong Kong ETF (EWH)
Guangzhou Baiyunshan Pharmaceutical Holdings Company Business Overview & Revenue Model
Guangzhou Baiyunshan Pharmaceutical Holdings Company Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 74.52B | 74.99B | 75.52B | 70.79B | 69.01B | 61.67B | Gross Profit |
| 12.05B | 12.52B | 14.19B | 13.28B | 13.23B | 10.44B | EBIT |
| 3.78B | 3.60B | 5.12B | 5.07B | 4.79B | 3.67B | EBITDA |
| 4.10B | 4.90B | 6.49B | 5.00B | 5.82B | 4.68B | Net Income Common Stockholders |
| 3.02B | 2.84B | 4.06B | 3.97B | 3.72B | 2.92B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 18.47B | 18.27B | 21.31B | 22.56B | 22.38B | 19.47B | Total Assets |
| 56.89B | 81.68B | 78.59B | 74.67B | 66.12B | 59.76B | Total Debt |
| 6.65B | 12.37B | 11.70B | 11.43B | 9.92B | 9.56B | Net Debt |
| -11.82B | ― | -9.61B | -11.07B | -12.45B | -9.91B | Total Liabilities |
| 30.90B | 43.91B | 41.91B | 41.03B | 34.79B | 31.55B | Stockholders Equity |
| 24.18B | 35.90B | 34.92B | 32.07B | 29.06B | 26.14B |
| Cash Flow | Free Cash Flow | ||||
| 4.73B | 2.31B | 2.48B | 5.62B | 4.42B | ― | Operating Cash Flow |
| 1.10B | 3.44B | 4.10B | 7.00B | 5.67B | 585.19M | Investing Cash Flow |
| ― | ― | -3.11B | ― | ― | ― | Financing Cash Flow |
| 1.03B | ― | -1.98B | 45.95M | ― | 1.44B |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Technical Analysis
Guangzhou Baiyunshan Pharmaceutical Holdings Company Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | HK$104.41B | 22.71 | 13.20% | 2.20% | -9.60% | -27.18% | |
75 Outperform | $82.53B | 12.20 | 18.17% | 4.30% | 12.76% | 34.50% | |
74 Outperform | $35.91B | 13.31 | 14.56% | 4.50% | -5.37% | 6.28% | |
66 Neutral | $45.48B | 10.02 | 7.22% | 7.36% | -4.07% | -35.32% | |
66 Neutral | $85.31B | 44.96 | 6.14% | 1.22% | 7.63% | -24.23% | |
62 Neutral | €33.74B | 9.29 | 3.00% | ― | ― | ||
54 Neutral | $5.37B | 3.35 | -45.10% | 2.79% | 16.77% | -0.01% |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Corporate Events
Guangzhou Baiyunshan Pharmaceutical Holdings Company reported a decrease in both income from operations and net profit for the first quarter of 2025 compared to the same period in 2024. The company experienced a 2.06% decline in income from operations and a 6.99% decrease in net profit attributable to shareholders. Additionally, the net cash flow from operating activities saw a significant drop of 24.19%. Despite these declines, the total equity attributable to shareholders increased by 5.05%, indicating a stronger financial position.
Guangzhou Baiyunshan Pharmaceutical Holdings Company announced that its subsidiary, Guangzhou Pharmaceuticals Co., Ltd. (GP Corp.), has received approval for the public transfer and quotation of its shares on the National Equities Exchange and Quotations (NEEQ). This move allows GP Corp. to be governed as a non-listed public company while remaining a non-wholly owned subsidiary of Guangzhou Baiyunshan. The quotation on NEEQ will not significantly impact the financial position or operations of the parent company, maintaining its status as an independently listed entity.
Guangzhou Baiyunshan Pharmaceutical Holdings Company announced that its subsidiary, Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd., received approval from the Guangdong Provincial Drug Administration for changes to its ‘Drug Production License’. The approval allows the subsidiary to reduce its production scope, workshops, and production lines, which could streamline operations and potentially impact its manufacturing efficiency and cost structure.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has announced that its board of directors will meet on April 29, 2025, to review and approve the unaudited financial results for the first quarter of 2025. This meeting is significant as it provides insights into the company’s financial health and operational performance, which are crucial for stakeholders and investors monitoring the company’s market position and future prospects.
Guangzhou Baiyunshan Pharmaceutical Holdings Company announced its 2024 annual report, highlighting a consolidated net profit of RMB 2.84 billion attributable to shareholders. The company proposed a cash dividend of RMB 0.40 per share, amounting to a total of RMB 650.32 million, with undistributed profits carried forward. This financial performance and profit distribution plan reflect the company’s stable position in the pharmaceutical industry and its commitment to rewarding shareholders.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited announced a final cash dividend of RMB 0.4 per share for the financial year ending December 31, 2024. This announcement reflects the company’s ongoing commitment to returning value to its shareholders, although specific details regarding the payment date and other related information are yet to be disclosed.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has scheduled a board meeting for March 13, 2025, to review and approve the audited financial results for the year ending December 31, 2024. This meeting will be crucial for stakeholders as it will provide insights into the company’s financial health and operational performance over the past year.
Guangzhou Baiyunshan Pharmaceutical Holdings Company, through its subsidiary GP Corp., has engaged in a series of transactions involving the sale of accounts receivable to Industrial Securities Asset Management. The latest transaction, completed on February 28, 2025, involves the disposal of new underlying assets valued at RMB583,087,010.44. This transaction, when aggregated with previous similar transactions within a 12-month period, constitutes a disclosable transaction under Hong Kong’s Listing Rules, requiring reporting and announcement but not shareholder approval.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited announced the resignation of Mr. Wu Changhai from his roles as an executive director, a member of the Nomination and Remuneration Committee, and other positions within its subsidiaries due to work adjustments. His departure does not affect the statutory minimum number of board members or the board’s operations, and an election for a new director will be conducted following statutory procedures. The company expressed gratitude for Mr. Wu’s contributions during his tenure.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has announced the list of its board of directors and their respective roles and functions. This update on the board structure may influence the company’s strategic direction and operational efficiency, affecting its positioning in the pharmaceutical industry.